Research progress of interleukin 22 binding protein in inflammation related diseases

doi:10.11958/20220999

Abstract

Abstract:

Interleukin 22 binding protein (IL-22BP) is a soluble receptor homolog that binds to interleukin 22 (IL-22) with greater affinity than the membrane spanning receptor. IL-22BP can play a role in maintaining immune homeostasis by inhibiting its expression and combining with IL-22. This review will focus on the production, regulation, typing of IL-22BP and its research progress in inflammatory related diseases, and explore the feasibility of it as a therapeutic target.

Key words: interleukin 22, cytokine, immunity, interleukin 22 binding protein, inflammation related diseases

CLC Number:

R392.12

References 40

[1]	ZENEWICZ L A. IL-22 Binding Protein (IL-22BP) in the regulation of IL-22 biology[J]. Front Immunol, 2021, 12:766586. doi:10.3389/fimmu.2021.766586.
[2]	LÜCKE J, SABIHI M, ZHANG T, et al. The good and the bad about separation anxiety:Roles of IL-22 and IL-22BP in liver pathologies[J]. Semin Immunopathol, 2021, 43(4):591-607. doi:10.1007/s00281-021-00854-z.
[3]	LOPEZ D V, KONGSBAK-WISMANN M. Role of IL-22 in homeostasis and diseases of the skin[J]. APMIS, 2022, 130(6):314-322. doi:10.1111/apm.13221.
[4]	NGUYEN H M, TORRES J A, AGRAWAL S, et al. Nicotine impairs the response of lung epithelial cells to IL-22[J]. Mediators Inflamm, 2020, 2020:6705428. doi:10.1155/2020/6705428.
[5]	KEIR M, YI Y, LU T, et al. The role of IL-22 in intestinal health and disease[J]. J Exp Med, 2020, 217(3):e20192195. doi:10.1084/jem.20192195.
[6]	MÜHL H, BACHMANN M. IL-18/IL-18BP and IL-22/IL-22BP:Two interrelated couples with therapeutic potential[J]. Cell Signal, 2019, 63:109388. doi:10.1016/j.cellsig.2019.109388.
[7]	LUO J W, HU Y, LIU J, et al. Interleukin-22:A potential therapeutic target in atherosclerosis[J]. Mol Med, 2021, 27(1):88. doi:10.1186/s10020-021-00353-9.
[8]	MA Q, LUAN J, BAI Y, et al. Interleukin-22 in renal protection and its pathological role in kidney diseases[J]. Front Immunol, 2022, 13:851818. doi:10.3389/fimmu.2022.851818.
[9]	DE MOURA P R, WATANABE L, BLEICHER L, et al. Crystal structure of a soluble decoy receptor IL-22BP bound to interleukin-22[J]. FEBS Lett, 2009, 583(7):1072-1077. doi:10.1016/j.febslet.2009.03.006.
[10]	OUYANG W, O'GARRA A. IL-10 Family Cytokines IL-10 and IL-22:from basic science to clinical translation[J]. Immunity, 2019, 50(4):871-891. doi:10.1016/j.immuni.2019.03.020.
[11]	JONES B C, LOGSDON N J, WALTER M R. Structure of IL-22 bound to its high-affinity IL-22R1 chain[J]. Structure, 2008, 16(9):1333-1344. doi:10.1016/j.str.2008.06.005.
[12]	GUENDEL F, KOFOED-BRANZK M, GRONKE K, et al. Group 3 innate lymphoid cells program a distinct subset of IL-22BP-producing dendritic cells demarcating solitary intestinal lymphoid tissues[J]. Immunity, 2020, 53(5):1015-1032.e8. doi:10.1016/j.immuni.2020.10.012.
[13]	NINNEMANN J, WINSAUER C, BONDAREVA M, et al. TNF hampers intestinal tissue repair in colitis by restricting IL-22 bioavailability[J]. Mucosal Immunol, 2022, 15(4):698-716. doi:10.1038/s41385-022-00506-x.
[14]	PELCZAR P, WITKOWSKI M, PEREZ L G, et al. A pathogenic role for T cell-derived IL-22BP in inflammatory bowel disease[J]. Science, 2016, 354(6310):358-362. doi:10.1126/science.aah5903.
[15]	MARTIN J C, BERIOU G, HESLAN M, et al. Interleukin-22 binding protein (IL-22BP) is constitutively expressed by a subset of conventional dendritic cells and is strongly induced by retinoic acid[J]. Mucosal Immunol, 2014, 7(1):101-113. doi:10.1038/mi.2013.28.
[16]	WANG B, HAN D, LI F, et al. Elevated IL-22 in psoriasis plays an anti-apoptotic role in keratinocytes through mediating Bcl-xL/Bax[J]. Apoptosis, 2020, 25(9/10):663-673. doi:10.1007/s10495-020-01623-3.
[17]	GÓMEZ-FERNÁNDEZ P, LOPEZ DE LAPUENTE PORTILLA A, ASTOBIZA I, et al. The rare IL22RA2 signal peptide coding variant rs28385692 decreases secretion of IL-22BP isoform-1,-2 and -3 and is associated with risk for multiple sclerosis[J]. Cells, 2020, 9(1):175. doi:10.3390/cells9010175.
[18]	TREVEJO-NUNEZ G, ELSEGEINY W, AGGOR F E Y, et al. Interleukin-22 (IL-22) binding protein constrains IL-22 activity,host defense,and oxidative phosphorylation genes during pneumococcal pneumonia[J]. Infect Immun, 2019, 87(11):e00550-19. doi:10.1128/IAI.00550-19.
[19]	KARTASHEVA-EBERTZ D M, POL S, LAGAYE S. Retinoic acid:A new old friend of IL-17A in the immune pathogeny of liver fibrosis[J]. Front Immunol, 2021, 12:691073. doi:10.3389/fimmu.2021.691073.
[20]	TAMEHIRO N, NISHIDA K, SUGITA Y, et al. Ras homolog gene family H(RhoH)deficiency induces psoriasis-like chronic dermatitis by promoting T_H17 cell polarization[J]. J Allergy Clin Immunol, 2019, 143(5):1878-1891. doi:10.1016/j.jaci.2018.09.032.
[21]	VOGLIS S, MOOS S, KLOOS L, et al. Regulation of IL-22BP in psoriasis[J]. Sci Rep, 2018, 8(1):5085. doi:10.1038/s41598-018-23510-3.
[22]	SABIHI M, BÖTTCHER M, PELCZAR P, et al. Microbiota-dependent effects of IL-22[J]. Cells, 2020, 9(10):2205. doi:10.3390/cells9102205.
[23]	HEBERT K D, MCLAUGHLIN N, GALEAS-PENA M, et al. Targeting the IL-22/IL-22BP axis enhances tight junctions and reduces inflammation during influenza infection[J]. Mucosal Immunol, 2020, 13(1):64-74. doi:10.1038/s41385-019-0206-9.
[24]	HUBER S, GAGLIANI N, ZENEWICZ L A, et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine[J]. Nature, 2012, 491(7423):259-263. doi:10.1038/nature11535.
[25]	ZHUANG L, MA W, YAN J, et al. Evaluation of the effects of IL-22 on the proliferation and differentiation of keratinocytes in vitro[J]. Mol Med Rep, 2020, 22(4):2715-2722. doi:10.3892/mmr.2020.11348.
[26]	EKMAN A K, BIVIK EDING C, RUNDQUIST I, et al. IL-17 and IL-22 promote keratinocyte stemness in the germinative compartment in psoriasis[J]. J Invest Dermatol, 2019, 139(7):1564-1573.e8. doi:10.1016/j.jid.2019.01.014.
[27]	MARTIN J C, WOLK K, BERIOU G, et al. Limited presence of IL-22 binding protein,a natural IL-22 inhibitor,strengthens psoriatic skin inflammation[J]. J Immunol, 2017, 198(9):3671-3678. doi:10.4049/jimmunol.1700021.
[28]	FUKAYA T, FUKUI T, UTO T, et al. Pivotal role of IL-22 binding protein in the epithelial autoregulation of interleukin-22 signaling in the control of skin inflammation[J]. Front Immunol, 2018, 9:1418. doi:10.3389/fimmu.2018.01418.
[29]	BRUNNER P M, PAVEL A B, KHATTRI S, et al. Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab[J]. J Allergy Clin Immunol, 2019, 143(1):142-154. doi:10.1016/j.jaci.2018.07.028.
[30]	JINNOHARA T, KANAYA T, HASE K, et al. IL-22BP dictates characteristics of Peyer's patch follicle-associated epithelium for antigen uptake[J]. J Exp Med, 2017, 214(6):1607-1618. doi:10.1084/jem.20160770.
[31]	WEI H X, WANG B, LI B. IL-10 and IL-22 in mucosal immunity:Driving protection and pathology[J]. Front Immunol, 2020, 11:1315. doi:10.3389/fimmu.2020.01315.
[32]	PEREZ L G, KEMPSKI J, MCGEE H M, et al. TGF-β signaling in Th17 cells promotes IL-22 production and colitis-associated colon cancer[J]. Nat Commun, 2020, 11(1):2608. doi:10.1038/s41467-020-16363-w.
[33]	KEMPSKI J, GIANNOU A D, RIECKEN K, et al. IL22BP mediates the antitumor effects of lymphotoxin against colorectal tumors in mice and humans[J]. Gastroenterology, 2020, 159(4):1417-1430.e3. doi:10.1053/j.gastro.2020.06.033.
[34]	STOY S, LAURSEN T L, GLAVIND E, et al. Low interleukin-22 binding protein is associated with high mortality in alcoholic hepatitis and modulates interleukin-22 receptor expression[J]. Clin Transl Gastroenterol, 2020, 11(8):e00197. doi:10.14309/ctg.0000000000000197.
[35]	KLEINSCHMIDT D, GIANNOU A D, MCGEE H M, et al. A protective function of IL-22BP in ischemia reperfusion and acetaminophen-induced liver injury[J]. J Immunol, 2017, 199(12):4078-4090. doi:10.4049/jimmunol.1700587.
[36]	SCHWARZKOPF K, RÜSCHENBAUM S, BARAT S, et al. IL-22 and IL-22-binding protein are associated with development of and mortality from acute-on-chronic liver failure[J]. Hepatol Commun, 2019, 3(3):392-405. doi:10.1002/hep4.1303.
[37]	DE BRITO R J V C, DO CARMO R F, SILVA B M S, et al. Liver expression of IL-22,IL-22R1 and IL-22BP in patients with chronic hepatitis C with different fibrosis stages[J]. Cytokine, 2022, 150:155784. doi:10.1016/j.cyto.2021.155784.
[38]	ABOOD R N, MCHUGH K J, RICH H E, et al. IL-22-binding protein exacerbates influenza,bacterial super-infection[J]. Mucosal Immunol, 2019, 12(5):1231-1243. doi:10.1038/s41385-019-0188-7.
[39]	LINDAHL H, GUERREIRO-CACAIS A O, BEDRI S K, et al. IL-22 binding protein promotes the disease process in multiple sclerosis[J]. J Immunol, 2019, 203(4):888-898. doi:10.4049/jimmunol.1900400.
[40]	SERTORIO M, HOU X, CARMO R F, et al. IL-22 and IL-22 binding protein (IL-22BP)regulate fibrosis and cirrhosis in hepatitis C virus and schistosome infections[J]. Hepatology, 2015, 61(4):1321-1331. doi:10.1002/hep.27629.

Research progress of interleukin 22 binding protein in inflammation related diseases

Cite this article

RichHTML

PDF (PC)

Knowledge

Abstract

share this article

References 40

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	SHAN Zihong, HU Xiaoqing, LI Feng, HUANG Yongkun. Research progress on the role and mechanism of 5-hydroxytryptamine in gastrointestinal diseases [J]. Tianjin Medical Journal, 2024, 52(4): 438-442.
[2]	ZHANG Wenchao, YANG Xuehui, YIN Tao, WANG Ruijian, ZHANG Mengmeng. The relationship between plasma sCD163/sTWEAK ratio and prognosis in patients with spontaneous acute cerebral hemorrhage [J]. Tianjin Medical Journal, 2024, 52(3): 297-301.
[3]	YAO Qian, WANG Jing, CHENG Na. Observation of curative effect of Shenqu Xiaoshi oral liquid on rotavirus infectious diarrhea in children [J]. Tianjin Medical Journal, 2024, 52(12): 1296-1300.
[4]	ZHANG Jie, MIAO Naiying, LI Huan, LIU Xinjian. Effects of octreotide on fecal characteristics and humoral immunity in neonates with necrotizing enterocolitis [J]. Tianjin Medical Journal, 2024, 52(12): 1331-1334.
[5]	QIN Zongbi, XU Aiqin, CAI Xiang, QIU Baiyi, WANG Shoufan, LI Linghua, ZHU Lihong. Effects of berberine on skin damage in rats with chronic eczema by regulating PI3K/AKT/NF-κB signaling pathway [J]. Tianjin Medical Journal, 2023, 51(8): 834-840.
[6]	ZHANG Xiaoyu, REN Yue, LIU Wei, MIAO Yanling, ZHANG Hui, JIN Lijun, ZHANG Hengle, KANG Xiaoning, BAI Jie, WANG Zunyi. Clinical efficacy of neoadjuvant chemotherapy combined with PD-1 inhibitor in the treatment of triple negative breast cancer [J]. Tianjin Medical Journal, 2023, 51(8): 847-850.
[7]	WANG Hongjun, SUN Xingxing, ZHANG Runlian. Study on the effect of Shengyang Yiwei Decoction on the immune function of rats with lung cancer based on PI3K/Akt/NF-κB signal pathway [J]. Tianjin Medical Journal, 2023, 51(7): 739-745.
[8]	YANG Yutao, WANG Yuan, XIE Jiaxin, FU Xiafei. Isolation, identification and ovarian uptake of exosomes derived from human bone marrow mesenchymal stem cells [J]. Tianjin Medical Journal, 2023, 51(5): 468-472.
[9]	LI Jianbin, HAN Ting, WU Rui. Exploring the correlation between immune function and poor prognosis in alloimmune recurrent miscarriage [J]. Tianjin Medical Journal, 2023, 51(11): 1217-1220.
[10]	TAN Anjun, YANG Jingjing, LI Tianrong. Relationship between irisin and newly diagnosed type 2 diabetes mellitus [J]. Tianjin Medical Journal, 2023, 51(1): 91-94.
[11]	DU Peng, WANG Feng, CHEN Xiaobo, ZHENG Yan, WU Qianqian, LIU Weijun, WANG Yuliang. Impact of age on the biological properties of human adipose tissue-derived mesenchymal stromal cells [J]. Tianjin Medical Journal, 2022, 50(9): 912-916.
[12]	CUI Yaqiong, LIU Wei. COVID-19 infection-associated multisystem inflammatory syndrome and cytokine storms in children [J]. Tianjin Medical Journal, 2022, 50(12): 1340-1344.
[13]	WANG Zhi-ying, YANG Qiu-xia, TIAN Xin-li, LIN Xue-xia△. Study on the mechanism of silicon-containing hydroxyapatite regulating macrophage [J]. Tianjin Medical Journal, 2021, 49(9): 910-915.
[14]	SUN Leng-bing, GONG Jian, LIU Qiao△. Research progress on the proliferation mechanism of keratinocytes in psoriasis [J]. Tianjin Medical Journal, 2021, 49(5): 545-549.
[15]	WAN Fang, MA Li-fang. Study on the mechanism of improving the activity of human retinal pigment epithelial cells by lutein through the SIRT1/NLRP3 signaling pathway #br# [J]. Tianjin Medical Journal, 2021, 49(2): 131-135.